NCT00093821View on ClinicalTrials.gov

Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

August 31, 2007

Conditions
Childhood Chronic Myelogenous LeukemiaChildhood Desmoplastic Small Round Cell TumorDisseminated NeuroblastomaMetastatic Childhood Soft Tissue SarcomaMetastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorMetastatic OsteosarcomaPreviously Treated Childhood RhabdomyosarcomaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Soft Tissue SarcomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent Osteosarcoma
Interventions
DRUG

tanespimycin

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00093821 - Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors | Biotech Hunter | Biotech Hunter